Page 5 - Heart Failure Guidelines

Pediatric Heart Failure Guidelines

Medical Management for ARVC ............................................................................................33
Follow up for ARVC ...............................................................................................................33
Chemotherapy Induced Cardiomyopathy ..................................................................................34

Additional Evaluation for Patient with Chemotherapy Induced Cardiomyopathy ....................34
Medical Management Chemotherapy Induced Cardiomyopathy ............................................34
Follow-up Schedule for Chemotherapy Induced Cardiomyopathy ..........................................34
Neuromuscular Disorder Associated Cardiomyopathy ..............................................................35

Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .35
Introduction ...............................................................................................................................35
Initial Evaluation ........................................................................................................................35
Ongoing Management ...............................................................................................................35

Dose escalation plan (outpatient monitoring) .........................................................................36
Imaging .....................................................................................................................................37
Arrhythmia Screening ................................................................................................................37
Advanced Therapies .................................................................................................................37
Myocarditis ................................................................................................................................38
Additional Evaluation for possible Myocarditis .......................................................................38
Medical Management Myocarditis .........................................................................................38
Immunotherapy Management Myocarditis .............................................................................38
Follow-up Schedule for Myocarditis .......................................................................................39

Medication Doses .....................................................................................................................40
Anticoagulation Schedules ........................................................................................................42

Updated 4/22/2019 page 5